NASDAQ$ITOS
iTeos Therapeutics Inc · Q4 2024 earnings
Q4 2024 earnings · · Before market open · Investor relations
Briefing
iTeos Therapeutics reported its fourth quarter and full year 2024 financial results, highlighting a net loss of $43.7 million and providing business updates.
iTeos Therapeutics reported a net loss of $43.7 million for the fourth quarter of 2024, compared to a net loss of $30.6 million in the same period of 2023. The company's cash and investments position stood at $655.0 million as of December 31, 2024, and is expected to provide runway through 2027.
- Net loss for Q4 2024 was $43.7 million, an increase from $30.6 million in Q4 2023.
- R&D expenses increased to $37.5 million in Q4 2024, up from $27.9 million in Q4 2023, driven by the GALAXIES Lung-301 Phase 3 trial and other programs.
- G&A expenses decreased slightly to $11.8 million in Q4 2024 from $12.4 million in Q4 2023.
- Cash and investment position was $655.0 million as of December 31, 2024, providing a projected runway through 2027.
Headline financials
Revenue & EPS history
iTeos Therapeutics · Revenue · Quarterly
$0
Forward guidance
iTeos Therapeutics anticipates a breakthrough year in 2025, with key milestones including topline interim data from GALAXIES Lung-201 and continued advancement of its clinical-stage programs, supported by a strong cash position.
Tailwinds
- Topline interim data from GALAXIES Lung-201 with >240 patients anticipated in 2Q25.
- Interim datasets from GALAXIES H&N-202 and TIG-006 HNSCC with ~200 patients anticipated in 2025.
- Completed enrollment of second dose cohort of EOS-984 + pembrolizumab combination in ongoing Phase 1 trial.
- EOS-215 Phase 1 trial TRM-010 patient enrollment anticipated to begin in 2Q25.
- Cash balance and investment balance of $655.0 million as of December 31, 2024 expected to provide runway through 2027.
Headwinds
- Expected benefits and opportunities related to the agreement between iTeos and GSK may not be realized or may take longer to realize.
- Success in preclinical testing and early clinical trials does not ensure that later clinical trials will be successful.
- Interim and early data may change as more patient data become available and are subject to audit and verification procedures.
- Data for product candidates may not be sufficient for obtaining regulatory approval to move into later stage trials or to commercialize products.
- iTeos may encounter unanticipated costs or may expend cash more rapidly or more slowly than currently anticipated.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 6 quarterly earnings reports · overlaid with Q4 2024
+0.8%
Avg return
Earnings day
+7.3%
Avg return
5 days after
+11.8%
Avg return
30 days after
38%
8 / 21 earnings
Positive
+39.6%
Q1 2024
Best reaction
-11.1%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | — | — | — | |
| Q2 2025 | +0.2% | +0.0% | — | |
| Q1 2025 | -0.4% | +13.3% | +52.2% | |
| Q4 2024 | -3.7% | -6.4% | -11.4% | |
| Q3 2024 | -5.9% | -12.4% | -15.6% | |
| Q2 2024 | -3.4% | +1.4% | -3.1% | |
| Q1 2024 | +39.6% | +47.5% | +36.9% | |
| Q4 2023 | +5.1% | +8.0% | +12.0% | |
| Q3 2023 | -3.1% | — | — | |
| Q2 2023 | -2.6% | — | — | |
| Q1 2023 | -0.8% | — | — | |
| Q4 2022 | -7.7% | — | — | |
| Q3 2022 | +16.2% | — | — | |
| Q2 2022 | -9.4% | — | — | |
| Q1 2022 | +3.2% | — | — | |
| Q4 2021 | -3.6% | — | — | |
| Q3 2021 | +1.4% | — | — | |
| Q2 2021 | -1.5% | — | — | |
| Q1 2021 | +8.5% | — | — | |
| Q4 2020 | -11.1% | — | — | |
| Q3 2020 | -4.2% | — | — | |
| Q2 2020 | +0.0% | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro